FDA advisory panels for Capricor and Replimune highlight need for rare-disease specialist input

Recent FDA advisory committee meetings reviewing therapies from Capricor Therapeutics and Replimune produced markedly different outcomes, underscoring how the agency’s reliance on specialist input can affect patient access.

The author argues that generalist FDA reviewers lack the depth required to evaluate treatments for complex rare conditions such as Duchenne muscular dystrophy, amyotrophic lateral sclerosis, Huntington's disease and spinocerebellar ataxia, creating a dangerous double standard.

With more than 7,000 rare diseases affecting roughly 30 million Americans, it is unrealistic to expect the FDA to possess disease‑specific expertise across the board. Instead, the piece urges the agency to heed the opinions of physicians who specialize in these disorders.

A congressional advisory panel cited in the article also recommended supportive policies for rare‑disease drug development, including a finalized platform designation and other measures to streamline approvals.

Overall, the commentary calls for a shift in FDA review practices toward greater reliance on rare‑disease specialists to improve outcomes for patients with unmet medical needs.